NPA president and CEO Daniel Fabricant, PhD, argues that FDA does not need new authorities to regulate the CBD market and that determining a safe daily intake level for the substance should be an integral part of that process.
Read more about it via https://www.nutraingredients-usa.com/Article/2021/09/08/NPA-Setting-safety-limit-on-CBD-key-part-of-regulatory-process?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS
No comments:
Post a Comment